Latest Competition News

Sky Metals Limited reported its December 2024 quarterly cash flow, revealing ongoing exploration expenditures alongside a robust cash position of A$6.375 million.

Knosys Limited reports a record Annual Recurring Revenue of $9.7 million, driven by major enterprise contract renewals, while gearing up for the March 2025 launch of its Libero Library App.

Pioneer Lithium Limited has lifted its trading suspension following the announcement of a proposed material acquisition and capital raising, signaling a pivotal moment for the company’s growth strategy.

Element 25 Limited reports a transformative quarter with a 142% resource increase at Butcherbird, a compelling $561 million NPV feasibility study, and a $268 million US Department of Energy grant to advance its Louisiana battery-grade manganese refinery.

Almonty Industries has secured an exclusive offtake agreement with South Korea’s SeAH Group to supply 100% of molybdenum from its Sangdong project, underpinning financial stability and strengthening local supply chains.

Element 25 Limited has successfully raised AU$2.85 million through an at-the-market share placement with Acuity Capital, issuing 8.7 million shares at a premium price to bolster its working capital.

FirstWave reports a stable Q2 FY25 with no cash burn for the second consecutive quarter, maintaining cash reserves at $1.68 million while securing key client contract renewals and launching a promising new product.

Argenica Therapeutics has dosed 80% of patients in its Phase 2 stroke trial and gained FDA orphan drug designations for its second candidate, ARG-006. The company reports a cash-positive quarter with $15 million in reserves.

OpenLearning Limited reported a 23% year-on-year increase in SaaS annual recurring revenue to $2.335 million in Q4 FY24, driven by strong growth in AI-powered products and strategic partnerships. The company also cut net operating cash outflows by over half, signaling improved operational efficiency.

NEXION Group reported a robust 30% increase in cash receipts for Q2 FY25, driven by strong sales growth and new satellite sector contracts. The company is actively expanding its footprint in Southeast Asia while funding ongoing M&A activities through convertible notes.

Argenica Therapeutics has received a positive safety review from its independent DSMB for the Phase 2 trial of ARG-007 in acute ischaemic stroke patients, with dosing now 86% complete and full recruitment expected by early Q2 2025.

Syrah Resources faces significant operational disruption at its Balama graphite mine due to ongoing protests, declaring force majeure while advancing its US-based Vidalia facility amid strong EV market growth.